Through the use of measurement, control, information technology and life science, radically improve productivity across the entire value chain, from basic research to logistics and services.
Model of our solution
Doted lines indicate Solutions under development.
We have 30 years of experience in this life science field and will respond to customer's problem solving with cutting-edge solutions.
Yokogawa's in-line sensors and advanced control algorithms will stabilize and improve the efficiency of the cell culture processes for biopharmaceutical production.
YOKOGAWA is working on the development of single cell mass spectrometry and single cell gene analysis. In order to analyze one cell with high sensitivity, we are developing a method of collecting target cells while keeping position information under observing cells with confocal scanner.
Yokogawa is a proponent of a robust genetic testing method for food, drink, and drug contamination that can be carried out with overwhelming speed and simplicity.
YOKOGAWA aims to cost reductions and improve safety by providing a structure and data-management platform for unified management of information related to cellular and regenerative therapies.
Yokogawa is contributing to the development of the pharmaceutical industry based on its performance of introducing over 1,000 systems in the areas of drug substances, pharmaceutical products, and biotechnology.
In addition to daily improvement cycles, Yokogawa will use IIoT to support create environments that do not cause defects and that are designed to completely reduce losses.
Life Innovation Business Vision
In the Life Innovation organization, we established the business vision "We will lead the world in advancing Bio Industrial Autonomy and contribute to a future embracing global harmony" with the aim of clarifying future developments of the business, its scope and direction. In this vision, we have targeted the "Pharmaceutical, Food, Beverage & Biotech" sectors and aim to further expand our business, centering on theseindustries, by taking advantage of our strengths in "Measurement, Imaging, Analysis, Diagnosis, Integration" and Yokogawa core technologies.
Four business segments aiming to realize BIA
Life science
By contributing to the development of measurement and analysis technologies, we will solve problems that limit research progress and create a world where scientists can concentrate on science.
Bioprocess
Using real-time monitoring and software innovations, we will create a virtual world of "Digital Twin" where experimental simulations are leveraged to realize precision predictive control
Pharmaceutical
We analyze and control the information obtained from all manufacturing activities and solve issues related to raw material quality, facility degradation, transmission of technology, and production processes to improve work environment and worker safety.
Food & Beverage
In addition to improving optimal and efficient automatic processes based on demand forecasting, we will assist with quality improvements that include taste attributes, and promote autonomous operation that grows independent of human intervention.
Life Innovation Business Headquarters’ contribution towards the fight against Novel Coronavirus Disease (COVID-19)
In April 2018, Yokogawa established the Life Innovation Business Headquarters with the goal of promoting well-being for all. In addition to engaging in our existing life science and manufacturing solutions businesses targeting the pharmaceutical and food industries, the headquarters works to develop new products and services and provides one-stop solutions that revolutionize productivity throughout the pharmaceutical and food industry value chain, from basic research to manufacturing, logistics, and services.
Yokogawa has more than 30 years’ experience in the life science field. The CSU spinning disk confocal scanner series is our core strength, and over 3,000 units have been sold globally. Other products, including a live cell imaging system, a high-content analysis system and single cell analysis solution also support leading life science studies. In the field of manufacturing solutions, over 1,000 Yokogawa manufacturing, production, and quality management systems and control systems have been introduced in the pharmaceutical industry.
In response to the novel coronavirus (COVID-19), Yokogawa has been taking various measures to prevent transmission of the virus while working to minimize the impact on customers. We are also contributing to the fight against COVID-19 by collaborating with research institutes globally and supporting research to develop new medication or vaccines. Yokogawa will continue to work with customers and business partners in an effort to resolve the crisis society is facing.
Please contact our sales and service representatives if you have any interest in our products, or you can send inquiries from the form below.
In August 2017, Yokogawa announced its long-term sustainability goals (Three Goals) for the year 2050. Yokogawa established these goals to contribute to achieving Net-zero emissions, Circular economy and Well-being. In April 2018, Yokogawa strengthened the business structure of its life innovation business with the aim of achieving one of these goals, well-being.
Achieve a Well-being
- With the world’s population aging, the importance of the pharmaceutical and food industries to ensure that people can live safe and secure lives with peace of mind is growing.
- With the world’s population increasing and aging in major countries including emerging countries, it will certainly become more difficult to stably supply the necessary medical care and safe food to many people.
- In the 2030 Agenda for Sustainable Development, adopted by the United Nations in 2015, well-being is defined as a “state of physical, mental and social well being.” Yokogawa supports people’s health and prosperity, as well as a safe and comfortable workplace, in a wide range of fields, such as life sciences and drug discovery.
Establish a life innovation business
- Expand business based on existing pharmaceutical/food industry businesses and new technologies and products that are under development.
- Through the use of measurement, control, and information technology, radically improve productivity across the entire value chain, from basic research to logistics and services.
| January | 8,2021 |
Sales release : Advanced Control Bioreactor System BR1000 was released. |
| October | 23,2020 |
YOKOGAWA Sponsored Webinar Abstract: |
| August | 21,2020 |
Bioprocessing Summit 2020 Virtual Dates: August 24-28 EST, 2020 Yokogawa introduce about advanced automated bioreactor controller system. Join us at our virtual tradeshow booth. We look forward to connecting with you. |
| August | 20,2020 |
Discovering Potential Covid-19 Therapies using High Content Screening |
| June | 22,2020 |
YOKOGAWA Sponsored Webinar July 29, 2020 11 am to 12 pm EDT (July 30, 2020 0 am to 1 am JST) Integration of soft-sensor technologies with CHO-cell predictive models for improved bioreactor automation & process control Abstract: |
| June | 5,2020 |
BIO Digital 2020 June 8-12, 2020 We will participate in partnering event and hold a corporate seminar about Advanced Control Bioreactor System. |
| March | 18,2020 |
Sales release : Single-cell Analysis Solution Single Cellome Unit SU10 |
| November | 18,2018 |
ASCB/EMBO 2019 December 8-10, 2019 We will exhibit Spinning disk confocal "CSU-W1 SoRa" and high content analysis system "CellVoyager CQ1". Link to products -Tech talks- December 9, 3:00-4:00 pm – Theater 2, Learning Center Uniformizer, a new flat-top beam shaper for CSU-W1 & Introduction to new approach for single cell analysis Presenter: Naoki Ando: Product specialist of CSU, Masahiro Kajita: Project manager of “Single Cellome” Yokogawa continues to make improvements to provide the best products for biology researchers. So far, CSU has fulfilled the researchers' wish to take images fast, wide, clear and in super-resolution. This time, we will introduce the new option “Uniformizer” of our product “CSU-W1”. This unit uniformizes the laser illumination and enables quantitative imaging. This provides a large seamless montage image between each field. Furthermore, Yokogawa also takes new challenge for the next field, which is single cell analysis. As a trial, it had prototyped automated single cell sampling system, and it has possible to investigate the molecular characterization of each single cell. This tech talk will introduce 1) ”Uniformizer” and 2) new approach for single cell analysis, which could perform with confocal microscopy. |
We post our information to the following SNSs.
Please follow us.
Yokogawa Life Science
| @Yokogawa_LS | |
| Yokogawa Life Science | |
| Yokogawa Life Science |
Yokogawa's Official Social Media Account List
Exploring the technologies needed to achieve automatic control of cell culture processes.
Brochures
- Confocal scanner unit CSU-W1 (2.9 MB)
- Confocal Scanner Unit CSU-W1 SoRa
- Confocal scanner unit CSU-X1 (2.4 MB)
- High-throughput Cytological Discovery System CellVoyager CV8000 (2.5 MB)
- Confocal Quantitative Image Cytometer CQ1 (3.5 MB)
- High Content Analysis Software CellPathfinder (11.3 MB)
- Life Innovation Business (2.4 MB)
- High Content Data Management System CellLibrarian (747 KB)
Webinars
In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.
- Collaboration to widen use of N-NOSE cancer screening test -
- Supporting drug development research through the use of HCA and three-dimensional culture models -
- A system that ensures compliance with industry regulations and decreases risk to improve efficiency -
- Enhancing our business in the bioeconomy market -